Transforming Retinal Disease Management with Novel Therapies - Episode 9

Safety Considerations for New Therapies

Published on: 
, , , ,

Experts discuss the safety of aflibercept 8 mg, emphasizing familiarity, efficacy, and durability, supported by reassuring data from the two-year PULSAR and PHOTON studies.


In this segment, the discussion focuses on the safety considerations of aflibercept 8 mg, particularly in relation to intraocular inflammation (IOI) and retinal vasculitis. David Eichenbaum, MD asks Kenny Fan, MD, MBA about his concerns regarding safety considering the higher dose of aflibercept. Fan expresses confidence in the safety profile of aflibercept 8 mg, highlighting the advantage of switching patients to a drug they are already familiar with, while providing the opportunity of higher efficacy and durability. He mentions the reassuring safety data from the two-year PULSAR and PHOTON studies, emphasizing the absence of significant safety concerns such as IOI and increased intraocular pressure (IOP). Experts discuss label modifications for both aflibercept and faricimab related to the rare occurrence of retinal vasculitis. Diana Do, MD responds, acknowledging the label modification but underscores that the chance of retinal vasculitis is extremely low and rare. She emphasizes the overall excellent safety profile observed in the data, providing increased confidence in discussing safety issues with patients. The conversation highlights the importance of considering safety aspects when discussing treatment options with patients and how the latest data can influence the narrative around potential risks.

This summary was AI-generated and edited for clarity.